{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:36:50Z","timestamp":1793659010343,"version":"4.5.1"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lrjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.leukres.2016.03.005","type":"journal-article","created":{"date-parts":[[2016,3,22]],"date-time":"2016-03-22T12:19:18Z","timestamp":1458649158000},"page":"53-60","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Splenic marginal zone lymphoma: Prognostic factors, role of watch and wait policy, and other therapeutic approaches in the rituximab era"],"prefix":"10.1016","volume":"44","author":[{"given":"Salvatore","family":"Perrone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianna Maria","family":"D\u2019Elia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Annechini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonietta","family":"Ferretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Elena","family":"Tosti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Fo\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Pulsoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2016.03.005_bib0005","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/00000478-199205000-00004","article-title":"Splenic marginal zone cell lymphoma","volume":"16","author":"Schmid","year":"1992","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.leukres.2016.03.005_bib0010","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.3109\/10428194.2012.743655","article-title":"Splenic marginal zone lymphoma: a population-based study on the 2001\u20132008 incidence and survival in the United States","volume":"54","author":"Liu","year":"2013","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.leukres.2016.03.005_bib0015","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1002\/1097-0142(20010601)91:11<2001::AID-CNCR1225>3.0.CO;2-3","article-title":"The spleen as a diagnostic specimen","volume":"91","author":"Kraus","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2016.03.005_bib0020","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.autrev.2004.03.004","article-title":"Inflamm-aging: autoimmunity, and the immune-risk phenotype","volume":"3","author":"Boren","year":"2004","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.leukres.2016.03.005_bib0025","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nature01322","article-title":"Inflammation and cancer","volume":"420","author":"Coussens","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.leukres.2016.03.005_bib0030","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/sj.leu.2405068","article-title":"Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria","volume":"22","author":"Matutes","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2016.03.005_bib0035","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1182\/blood-2002-10-3230","article-title":"Hepatitis C virus and B-cell non-Hodgkin lymphomas: an Italian multicenter case-control study","volume":"102","author":"Mele","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.03.005_bib0040","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/cncr.11893","article-title":"Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting features but similar morphologic and phenotypic profiles","volume":"100","author":"Arcaini","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2016.03.005_bib0045","doi-asserted-by":"crossref","first-page":"e2016006","DOI":"10.4084\/mjhid.2016.006","article-title":"Infectious aetiology of marginal zone lymphoma and role of anti-Infective therapy","volume":"8","author":"Perrone","year":"2016","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"10.1016\/j.leukres.2016.03.005_bib0050","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3816\/CLM.2002.n.010","article-title":"Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients","volume":"3","author":"Thieblemont","year":"2002","journal-title":"Clin. Lymphoma"},{"key":"10.1016\/j.leukres.2016.03.005_bib0055","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1182\/blood.V93.5.1778","article-title":"Hepatitis C virus infection in patients with overt B-cell non-Hodgkin's lymphoma in a French center","volume":"93","author":"Germanidis","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.03.005_bib0060","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1093\/jncimonographs\/lgu011","article-title":"Medical history, lifestyle, family history, and occupational risk factors for marginal zone lymphoma: the interLymph non-Hodgkin lymphoma subtypes project","volume":"2014","author":"Bracci","year":"2014","journal-title":"J. Natl. Cancer Inst. Monogr."},{"issue":"6","key":"10.1016\/j.leukres.2016.03.005_bib0065","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1111\/bjh.13908","article-title":"High prevalence of splenic marginal zone lymphoma among patients with acquired C1 inhibtor deficiency","volume":"172","author":"Castelli","year":"2016","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2016.03.005_bib0070","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S1470-2045(03)00981-1","article-title":"Splenic marginal-zone lymphoma: a distinct clinical and pathological entity","volume":"4","author":"Thieblemont","year":"2003","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.leukres.2016.03.005_bib0075","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1182\/blood-2005-11-4659","article-title":"Splenic marginal zone lymphoma: a prognostic model for clinical use","volume":"107","author":"Arcaini","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.03.005_bib0080","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1182\/blood.V100.5.1648.h81702001648_1648_1654","article-title":"Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 60 patients","volume":"100","author":"Chacon","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.03.005_bib0085","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1046\/j.1365-2141.1996.d01-1711.x","article-title":"Splenic lymphoma with villous lymphocytes: clinical presentation, biology and prognostic factors in a series of 100 patients. Groupe Francais d'Hematologie Cellulaire (GFHC)","volume":"93","author":"Troussard","year":"1996","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2016.03.005_bib0090","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1002\/cncr.20596","article-title":"Splenic marginal zone lymphoma with or without villous lymphocytes. Hematologic findings and outcomes in a series of 57 patients","volume":"101","author":"Iannitto","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2016.03.005_bib0095","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1046\/j.1365-2141.2003.04165.x","article-title":"Prognostic features of splenic lymphoma with villous lymphocytes: a report on 129 patients","volume":"120","author":"Parry-Jones","year":"2003","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2016.03.005_bib0100","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1600-0609.2005.00578.x","article-title":"Assessment of the frequency of additional cancers in patients with splenic marginal zone lymphoma","volume":"76","author":"Iannitto","year":"2006","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.leukres.2016.03.005_bib0105","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1097\/00000478-200110000-00007","article-title":"Progression to large B-cell lymphoma in splenic marginal zone lymphoma: a description of a series of 12 cases","volume":"25","author":"Camacho","year":"2001","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.leukres.2016.03.005_bib0110","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1093\/annonc\/mdv368","article-title":"Histologic transformation in marginal zone lymphomas","volume":"26","author":"Conconi","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.leukres.2016.03.005_bib0115","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/bjh.12011","article-title":"Risk stratification for Splenic Marginal Zone Lymphoma based on haemoglobin concentration, platelet count, high lactate dehydrogenase level and extrahilar lymphadenopathy: development and validation on 593 cases","volume":"159","author":"Montalban","year":"2012","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2016.03.005_bib0120","doi-asserted-by":"crossref","first-page":"929","DOI":"10.3109\/10428194.2013.818143","article-title":"Simplification of risk stratification for splenic marginal zone lymphoma: a point-based score for practical use","volume":"55","author":"Montalban","year":"2014","journal-title":"Leuk. Lymphoma"},{"issue":"September (18)","key":"10.1016\/j.leukres.2016.03.005_bib0125","doi-asserted-by":"crossref","first-page":"4174","DOI":"10.1158\/1078-0432.CCR-14-2759","article-title":"Genetics and prognostication in splenic marginal zone lymphoma: revelations from deep sequencing","volume":"15","author":"Parry","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.leukres.2016.03.005_bib0130","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1186\/s12885-015-1766-z","article-title":"Whole exome sequencing of microdissected splenic marginal zone lymphoma: a study to discover novel tumor-specific mutations","volume":"15","author":"Peveling-Oberhag","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.leukres.2016.03.005_bib0135","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","article-title":"A revised European\u2013American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group","volume":"84","author":"Harris","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.03.005_bib0140","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2008"},{"key":"10.1016\/j.leukres.2016.03.005_bib0145","doi-asserted-by":"crossref","unstructured":"M. Hallek, B.D. Cheson, D. Catovsky, F. Caligaris-Cappio, G. Dighiero, H. D\u00f6hner, et al., Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines (2008).","DOI":"10.1182\/blood-2007-06-093906"},{"key":"10.1016\/j.leukres.2016.03.005_bib0150","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J. Am. Stat. Assoc."},{"key":"10.1016\/j.leukres.2016.03.005_bib0155","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life-tables","volume":"34","author":"Cox","year":"1972","journal-title":"J. R. Stat. Soc. B"},{"key":"10.1016\/j.leukres.2016.03.005_bib0160","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/bjh.13320","article-title":"Outcomes in splenic marginal zone lymphoma: analysis of 107 patients treated in British Columbia","volume":"169","author":"Xing","year":"2015","journal-title":"Br. J. Haematol."},{"issue":"February (1)","key":"10.1016\/j.leukres.2016.03.005_bib0165","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s15010-015-0841-3","article-title":"High seroprevalence of HCV in the Abruzzo Region, Italy: results on a large sample from opt-out pre-surgical screening","volume":"44","author":"Polilli","year":"2016","journal-title":"Infection"},{"issue":"July","key":"10.1016\/j.leukres.2016.03.005_bib0170","article-title":"The epidemiological changes of HCV and HBV infections in the era of new antiviral therapies and the anti-HBV vaccine","volume":"3","author":"Stasi","year":"2015","journal-title":"J. Infect. Public Health"},{"key":"10.1016\/j.leukres.2016.03.005_bib0175","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1136\/jcp.2010.076810","article-title":"Hepatitis C virus infection is significantly associated with malignant lymphoma in Taiwan, particularly with nodal and splenic marginal zone lymphomas","volume":"63","author":"Chuang","year":"2010","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.leukres.2016.03.005_bib0180","first-page":"288","article-title":"The relationship between splenic marginal zone B-cell lymphoma and chronic liver disease associated with hepatitis C virus infection","volume":"14","author":"Moccia","year":"1999","journal-title":"Ann. Ital. Med. Int."},{"key":"10.1016\/j.leukres.2016.03.005_bib0185","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/BF02940322","article-title":"Hepatitis C virus infection and locally advanced splenic marginal zone lymphoma","volume":"13","author":"Szynglarewicz","year":"2007","journal-title":"Pathol. Oncol. Res."},{"key":"10.1016\/j.leukres.2016.03.005_bib0190","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1093\/annonc\/mdu166","article-title":"Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi","volume":"25","author":"Arcaini","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.leukres.2016.03.005_bib0195","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1053\/j.gastro.2014.10.038","article-title":"American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy","volume":"148","author":"Perrillo","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.leukres.2016.03.005_bib0200","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S1470-2045(14)70027-0","article-title":"Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial","volume":"15","author":"Ardeshna","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.leukres.2016.03.005_bib0205","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/bjh.13316","article-title":"A population-based study of prognosis in advanced stage follicular lymphoma managed by watch and wait","volume":"169","author":"El-Galaly","year":"2015","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2016.03.005_bib0210","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1365-2141.1991.tb04417.x","article-title":"Splenic lymphoma with villous lymphocytes: natural history and response to therapy in 50 cases","volume":"78","author":"Mulligan","year":"1991","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2016.03.005_bib0215","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.3109\/10428194.2013.861067","article-title":"Long-term follow-up analysis of 100 patients with splenic marginal zone lymphoma treated with splenectomy as first-line treatment","volume":"55","author":"Lenglet","year":"2014","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.leukres.2016.03.005_bib0220","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.3748\/wjg.v19.i24.3854","article-title":"Laparoscopic splenectomy for treatment of splenic marginal zone lymphoma","volume":"19","author":"Wu","year":"2013","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.leukres.2016.03.005_bib0225","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1634\/theoncologist.2012-0251","article-title":"Treatment of splenic marginal zone lymphoma with rituximab monotherapy: progress report and comparison with splenectomy","volume":"18","author":"Kalpadakis","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.leukres.2016.03.005_bib0230","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00277-013-1900-4","article-title":"Comparative outcomes of rituximab-based systemic therapy and splenectomy in splenic marginal zone lymphoma","volume":"93","author":"Olszewski","year":"2014","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.leukres.2016.03.005_bib0235","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.3109\/10428194.2015.1029925","article-title":"Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone lymphoma: a Fondazione Italiana Linfomi phase II study","volume":"56","author":"Iannitto","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.leukres.2016.03.005_bib0240","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.leukres.2016.03.005_bib0245","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/annonc\/mds643","article-title":"ESMO Consensus conferences: guidelines on malignant lymphomapart 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma","volume":"24","author":"Dreyling","year":"2013","journal-title":"Ann. Oncol."},{"issue":"December","key":"10.1016\/j.leukres.2016.03.005_bib0250","article-title":"Underutilization of radiation therapy in early-stage marginal zone lymphoma negatively impacts overall survival","volume":"3","author":"Ling","year":"2015","journal-title":"Pract. Radiat. Oncol."},{"key":"10.1016\/j.leukres.2016.03.005_bib0255","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/cncr.27773","article-title":"Survival of patients with marginal zone lymphoma: analysis of the surveillance, epidemiology, and end results database","volume":"119","author":"Olszewski","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2016.03.005_bib0260","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.3324\/haematol.2012.083386","article-title":"Recognizing nodal marginal zone lymphoma: recent advances and pitfalls. A systematic review","volume":"98","author":"van den Brand","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2016.03.005_bib0265","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.1002\/cncr.25325","article-title":"Marginal zone lymphomas: factors that affect the final outcome","volume":"116","author":"Mazloom","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2016.03.005_bib0270","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/bjh.12036","article-title":"Rituximab, used alone or in combination, is superior to other treatment modalities in splenic marginal zone lymphoma","volume":"159","author":"Else","year":"2012","journal-title":"Br. J. Haematol."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212616300327?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212616300327?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T06:26:22Z","timestamp":1718432782000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212616300327"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":54,"alternative-id":["S0145212616300327"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2016.03.005","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Splenic marginal zone lymphoma: Prognostic factors, role of watch and wait policy, and other therapeutic approaches in the rituximab era","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2016.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}